Actinium Pharmaceuticals Announces Key Hire in Clinical Supply Chain Organization as Company Expands To Accommodate Continued Growth
31 oct. 2016 07h00 HE
|
Actinium Pharmaceuticals
- Incoming Industry Veteran to Lead Clinical Supply Chain Operations and Architect the Build Out of the Anticipated Commercial Supply Chain NEW YORK, Oct. 31, 2016 (GLOBE NEWSWIRE) -- Actinium...
Actinium Pharmaceuticals Announces New Hires As Supply Chain Organization Expands To Accommodate Growth
26 oct. 2016 07h00 HE
|
Actinium Pharmaceuticals
- Incoming specialists to focus on Quality Control and Quality Assurance Aspects of Supply Chain NEW YORK, Oct. 26, 2016 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM)...
Actinium Pharmaceuticals Initiates Pursuit of Scientific Advice for Iomab-B from the European Medicines Agency
25 oct. 2016 07h00 HE
|
Actinium Pharmaceuticals
- Company is seeking guidance on development plan of Iomab-B for the EU market - Actinium’s small and medium-sized (SME) status and orphan designation results in a 100% reduction in...
Actinium Announces Acceptance of Actimab-A Data for Poster Presentation at American Society of Hematology Annual Meeting
19 oct. 2016 07h00 HE
|
Actinium Pharmaceuticals
NEW YORK, Oct. 19, 2016 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload...
Actinium Pharmaceuticals Granted Orphan Designation from the European Medicines Agency for Iomab-B
18 oct. 2016 07h00 HE
|
Actinium Pharmaceuticals
- Orphan designation is expected to provide increased communication and guidance from regulators and 10-year market exclusivity should marketing authorization be obtained - Orphan designation...
Actinium Announces Closing of Public Offering of Common Stock
04 oct. 2016 16h15 HE
|
Actinium Pharmaceuticals
NEW YORK, Oct. 04, 2016 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload...
Actinium Announces Pricing of Public Offering of Common Stock
29 sept. 2016 08h15 HE
|
Actinium Pharmaceuticals
NEW YORK, Sept. 29, 2016 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload...
Actinium Announces Proposed Public Offering of Common Stock
28 sept. 2016 16h10 HE
|
Actinium Pharmaceuticals
NEW YORK, Sept. 28, 2016 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload...
Actinium Announces Initiation of Phase 2 Clinical Trial of Actimab-A in Patients Newly Diagnosed with Acute Myeloid Leukemia Over Age 60
27 sept. 2016 07h00 HE
|
Actinium Pharmaceuticals
Webinar to be held at 9:00 AM ET to highlight Actimab-A Phase 2 clinical trial and protocol revisions agreed to by the FDAProtocol revisions agreed to by the FDA include the use of peripheral blast...
Actinium Pharmaceuticals to Sponsor and Participate in Be The Match® Walk+Run to Raise Awareness for Bone Marrow Transplant
26 sept. 2016 07h00 HE
|
Actinium Pharmaceuticals
NEW YORK, Sept. 26, 2016 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload...